Biomarker and Neurogenetics Core

生物标志物和神经遗传学核心

• 批准号: 10410387
• 负责人: M. Ilyas Kamboh
• 金额: $ 26.44万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-15 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10410387
• 关键词: Alzheimer disease detection; Alzheimer' s Disease; Alzheimer' s disease patient; Alzheimer' s disease therapy; Alzheimer’s disease biomarker; Amyloid beta-Protein; Ancillary Study; Archives; Biological Assay; Biological Markers; Blood; Blood specimen; Cerebrospinal Fluid; Clinical; Collection; Complex; Country; DNA; DNA Library; Data; Dementia; Deposition; Development; Early Diagnosis; Enzyme-Linked Immunosorbent Assay; Funding; Future; Genes; Genetic; Genetic Diseases; Genetic Markers; Genetic Polymorphism; Genetic Risk; Genetic study; Genomics; Genotype; Goals; Grant; Image; Immunoprecipitation; Individual; International; Late Onset Alzheimer Disease; Light; Magnetic Resonance Imaging; Mass Spectrum Analysis; Measures; Medical; Medical Device; Methods; Multicenter Trials; Nerve Degeneration; Neuronal Injury; Participant; Pathologic; Performance; Pittsburgh Compound-B; Plasma; Play; Positron-Emission Tomography; Publications; RNA; Research; Research Personnel; Research Project Grants; Resources; Risk Marker; Role; Sample Size; Sampling; Site; Standardization; Techniques; Testing; Universities; Validation; Variant; base; blood-based biomarker; case control; cost; data management; endophenotype; genetic architecture; genetic variant; genome wide association study; mass spectrometer; neurofilament; neurofilament protein L; neurogenetics; neuroimaging; neuropathology; novel; phenotypic biomarker; research clinical testing; tau Proteins

Core G: Biomarker and Neurogenetics Core (BNGC): Summary/Abstract: The Biomarker and Neurogenetics (BNG) Core builds on the existing strengths of genetics of dementia and Alzheimer’s disease (AD) biomarkers at the University of Pittsburgh. Over nearly 25 years, we have amassed DNA and plasma samples along with endophenotype data from approximately 12,000 University of Pittsburgh ADRC (PITT-ADRC) and non-ADRC participants. This rich resource has enabled our research team to play a significant role in understanding the complex genetic architecture of late-onset AD and AD-related endophenotypes. The goal of the BNG Core is to continue collecting and archiving DNA and blood samples from new and existing AD patients and controls in order to enlarge case-control and endophenotype samples and to augment the amount of existing DNA and plasma that would be critical to current and future efforts in identifying new genetic markers and plasma biomarkers for AD in Pittsburgh and at external sites. Specifically, we will collect and bank DNA and plasma from blood samples and obtain endophenotype data from ADRC and non-ADRC ancillary studies (aim1); generate APOE and other new genetic risk markers associated with AD and provide the genetic data to qualified investigators (aim 2); and generate plasma Aβ and neurofilament light (NFL) biomarkers data and provide this to studies assessing the utility of blood-based biomarkers to predict individual Aβ and tau deposition, as well as neurodegeneration, as determined by PET and MRI imaging.

核心G：生物标志物和神经遗传学核心（BNGC）：摘要/摘要： 生物标志物和神经遗传学 （BNG）核心建立在痴​​呆症和阿尔茨海默氏病（AD）生物标志物的现有遗传学强度的基础上 在匹兹堡大学。在近25年的时间里，我们聚集了DNA和血浆样品以及 来自匹兹堡大学（Pitt-ADRC）和非ADRC的大约12,000个匹兹堡大学的内表型数据 参与者。这种丰富的资源使我们的研究团队能够在理解 晚期AD和与广告相关的内表型的复杂遗传结构。 BNG核心的目标是 继续从新的和现有的AD患者和对照组中收集和存档DNA和血液样本 为了扩大病例对照和内表型样本，并增加现有DNA的量 对于确定新的遗传标记和血浆的当前和未来努力至关重要的等离子体 匹兹堡和外部地点的广告生物标志物。具体来说，我们将收集和银行DNA和等离子体 从血液样本中获取ADRC和非ADRC辅助研究（AIM1）的内表型数据； 生成与AD相关的APOE和其他新的遗传风险标志物，并将遗传数据提供给 合格的调查人员（AIM 2）；并产生血浆Aβ和神经丝（NFL）生物标志物数据和 将其提供给评估基于血液的生物标志物预测单个Aβ和TAU的效用的研究 由PET和MRI成像确定的沉积以及神经变性。